|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TROAP |
Gene summary for TROAP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TROAP | Gene ID | 10024 |
| Gene name | trophinin associated protein | |
| Gene Alias | TASTIN | |
| Cytomap | 12q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0007155 | UniProtAcc | Q12815 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10024 | TROAP | LZE2T | Human | Esophagus | ESCC | 9.54e-06 | 6.06e-01 | 0.082 |
| 10024 | TROAP | LZE7T | Human | Esophagus | ESCC | 1.02e-03 | 2.65e-01 | 0.0667 |
| 10024 | TROAP | LZE20T | Human | Esophagus | ESCC | 1.26e-02 | 3.60e-01 | 0.0662 |
| 10024 | TROAP | LZE24T | Human | Esophagus | ESCC | 5.13e-03 | 2.24e-01 | 0.0596 |
| 10024 | TROAP | LZE6T | Human | Esophagus | ESCC | 3.01e-06 | 2.49e-01 | 0.0845 |
| 10024 | TROAP | P1T-E | Human | Esophagus | ESCC | 2.97e-02 | 3.46e-01 | 0.0875 |
| 10024 | TROAP | P2T-E | Human | Esophagus | ESCC | 6.56e-15 | 6.93e-01 | 0.1177 |
| 10024 | TROAP | P4T-E | Human | Esophagus | ESCC | 1.46e-31 | 1.18e+00 | 0.1323 |
| 10024 | TROAP | P5T-E | Human | Esophagus | ESCC | 2.56e-16 | 3.18e-01 | 0.1327 |
| 10024 | TROAP | P8T-E | Human | Esophagus | ESCC | 1.66e-02 | 1.84e-01 | 0.0889 |
| 10024 | TROAP | P9T-E | Human | Esophagus | ESCC | 1.49e-16 | 4.56e-01 | 0.1131 |
| 10024 | TROAP | P10T-E | Human | Esophagus | ESCC | 1.62e-13 | 4.54e-01 | 0.116 |
| 10024 | TROAP | P11T-E | Human | Esophagus | ESCC | 4.74e-03 | 4.39e-01 | 0.1426 |
| 10024 | TROAP | P12T-E | Human | Esophagus | ESCC | 7.90e-03 | 1.39e-01 | 0.1122 |
| 10024 | TROAP | P15T-E | Human | Esophagus | ESCC | 1.53e-11 | 5.25e-01 | 0.1149 |
| 10024 | TROAP | P16T-E | Human | Esophagus | ESCC | 4.17e-05 | 1.74e-01 | 0.1153 |
| 10024 | TROAP | P17T-E | Human | Esophagus | ESCC | 1.15e-16 | 1.21e+00 | 0.1278 |
| 10024 | TROAP | P19T-E | Human | Esophagus | ESCC | 6.53e-04 | 6.22e-01 | 0.1662 |
| 10024 | TROAP | P20T-E | Human | Esophagus | ESCC | 3.20e-07 | 5.31e-01 | 0.1124 |
| 10024 | TROAP | P21T-E | Human | Esophagus | ESCC | 9.67e-18 | 4.88e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TROAP | SNV | Missense_Mutation | c.1457N>G | p.Ser486Cys | p.S486C | Q12815 | protein_coding | deleterious(0.01) | possibly_damaging(0.799) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TROAP | SNV | Missense_Mutation | c.329C>T | p.Ala110Val | p.A110V | Q12815 | protein_coding | deleterious(0.02) | benign(0.023) | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| TROAP | SNV | Missense_Mutation | c.257G>T | p.Ser86Ile | p.S86I | Q12815 | protein_coding | deleterious(0) | benign(0.118) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TROAP | SNV | Missense_Mutation | novel | c.1396N>A | p.Val466Ile | p.V466I | Q12815 | protein_coding | tolerated(0.19) | benign(0.14) | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
| TROAP | SNV | Missense_Mutation | c.2024N>G | p.Ser675Cys | p.S675C | Q12815 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-C8-A137-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| TROAP | deletion | Frame_Shift_Del | novel | c.233delN | p.Thr78AsnfsTer41 | p.T78Nfs*41 | Q12815 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TROAP | deletion | Frame_Shift_Del | novel | c.191delN | p.Asp64ValfsTer55 | p.D64Vfs*55 | Q12815 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| TROAP | SNV | Missense_Mutation | novel | c.77N>G | p.Ser26Cys | p.S26C | Q12815 | protein_coding | tolerated(0.12) | benign(0.118) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| TROAP | SNV | Missense_Mutation | c.699N>C | p.Glu233Asp | p.E233D | Q12815 | protein_coding | tolerated(0.35) | benign(0.022) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| TROAP | SNV | Missense_Mutation | c.2275N>C | p.Glu759Gln | p.E759Q | Q12815 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |